Hepion Pharmaceuticals Résultats passés
Passé contrôle des critères 0/6
Hepion Pharmaceuticals's earnings have been declining at an average annual rate of -24%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Informations clés
-24.0%
Taux de croissance des bénéfices
86.8%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 6.0% |
Taux de croissance des recettes | n/a |
Rendement des fonds propres | -796.4% |
Marge nette | n/a |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Pas de mise à jour
Recent updates
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely
Aug 10We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Apr 25We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Oct 27Hepion Pharma rises as company begins NASH treatment trial
Aug 31Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?
Jul 04Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH
Feb 17Hepion Pharmaceuticals: Facing The Momentous Year 2022
Jan 21Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep 21Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth
Sep 14Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
Sep 08Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)
May 26What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?
Feb 18Hepion Pharma cleared to advance final dosing cohort in NASH trial
Dec 29Hepion Pharma to begin CRV431 testing in COVID-19 patients
Dec 22Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study
Dec 10Hepion Pharma prices equity offering at $1.50
Nov 25Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow
Oct 31Ventilation des recettes et des dépenses
Comment Hepion Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 0 | -28 | 8 | 24 |
31 Mar 24 | 0 | -39 | 9 | 28 |
31 Dec 23 | 0 | -49 | 10 | 36 |
30 Sep 23 | 0 | -48 | 10 | 38 |
30 Jun 23 | 0 | -46 | 11 | 35 |
31 Mar 23 | 0 | -52 | 11 | 39 |
31 Dec 22 | 0 | -45 | 10 | 33 |
30 Sep 22 | 0 | -45 | 10 | 33 |
30 Jun 22 | 0 | -46 | 10 | 33 |
31 Mar 22 | 0 | -34 | 10 | 21 |
31 Dec 21 | 0 | -33 | 10 | 20 |
30 Sep 21 | 0 | -28 | 10 | 16 |
30 Jun 21 | 0 | -25 | 10 | 14 |
31 Mar 21 | 0 | -22 | 9 | 13 |
31 Dec 20 | 0 | -20 | 8 | 12 |
30 Sep 20 | 0 | -18 | 7 | 10 |
30 Jun 20 | 0 | -13 | 6 | 7 |
31 Mar 20 | 0 | -15 | 5 | 5 |
31 Dec 19 | 0 | -12 | 5 | 3 |
30 Sep 19 | 0 | -12 | 5 | 3 |
30 Jun 19 | 0 | -20 | 6 | 4 |
31 Mar 19 | 0 | -17 | 7 | 6 |
31 Dec 18 | 0 | -18 | 7 | 8 |
30 Sep 18 | 0 | -17 | 7 | 10 |
30 Jun 18 | 0 | -14 | 7 | 12 |
31 Mar 18 | 0 | -8 | 7 | 13 |
31 Dec 17 | 0 | -13 | 7 | 13 |
30 Sep 17 | 0 | -16 | 7 | 14 |
30 Jun 17 | 0 | -15 | 7 | 14 |
31 Mar 17 | 0 | -22 | 7 | 14 |
31 Dec 16 | 0 | -18 | 6 | 15 |
30 Sep 16 | 0 | -17 | 6 | 14 |
30 Jun 16 | 0 | -17 | 6 | 15 |
31 Mar 16 | 0 | -17 | 6 | 15 |
31 Dec 15 | 0 | -21 | 6 | 14 |
30 Sep 15 | 0 | -26 | 6 | 12 |
30 Jun 15 | 0 | -22 | 6 | 8 |
31 Mar 15 | 0 | -12 | 4 | 5 |
31 Dec 14 | 0 | -14 | 3 | 2 |
30 Sep 14 | 0 | -7 | 2 | 1 |
Des revenus de qualité: HEPA is currently unprofitable.
Augmentation de la marge bénéficiaire: HEPA is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: HEPA is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accélération de la croissance: Unable to compare HEPA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: HEPA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement des fonds propres
ROE élevé: HEPA has a negative Return on Equity (-796.38%), as it is currently unprofitable.